プロプラノロール医薬品の世界市場レポート 2025年

プロプラノロール医薬品市場規模は、今後数年間で力強い成長が見込まれます。2029年の年間平均成長率（CAGR）は5.5％で、13億7,000万米ドルに成長します。予測期間中の成長は、非侵襲的治療に対する需要の高まり、心血管治療薬の研究開発の増加、新興経済諸国におけるヘルスケア支出の増加、心血管治療における個別化医療の採用増加などの要因に起因すると考えられます。予測期間における主な動向には、徐放性製剤の進歩、高度なドラッグデリバリーシステムの開発、心血管治療における個別化医療の革新、薬物療法とデジタルヘルスツールの統合、不安や高血圧に対する併用療法の先進研究などがあります。

心血管疾患（CVDs）の有病率の上昇は、プロプラノロール医薬品市場の拡大を促進すると予想されます。CVDは心臓や血管に影響を及ぼす疾患群で、冠動脈疾患、心不全、脳卒中などの疾患が含まれます。心血管疾患の増加は不健康な食習慣によるところが大きく、加工食品や脂肪の過剰摂取はコレステロール値の上昇を招き、ひいては心臓関連の問題のリスクを高める。プロプラノロールは、心拍数を調節し血圧を下げることにより、これらの疾患を管理するのに有効であり、特に高血圧や不整脈の患者に有益です。プロプラノロールはまた、心臓の機能を高め、心臓発作や脳卒中のリスクを低減し、心臓血管全体の健康を改善します。例えば、2024年5月、米国疾病予防管理センター（CDC）は、2022年の心臓病による死亡者数は70万2,880人で、米国の死亡者数の5人に1人を占めると報告しました。その結果、心血管疾患の有病率の増加がプロプラノロールの需要を牽引しています。

プロプラノロール医薬品市場の主なプレーヤーは、患者のアドヒアランスと全体的な治療成果を改善するために、徐放性プロプラノロール製剤などの新興国市場の発展に注力しています。徐放性製剤は、時間をかけて徐々に薬剤が放出されるように設計されており、治療効果の持続性を確保し、頻繁な投与の必要性を低減します。これにより、患者のコンプライアンスが向上するだけでなく、治療効果も高まります。例えば、カナダに本社を置く製薬会社Lupin Pharma Canada Ltd.は2023年8月、インデラル長時間作用型（LA）の販売中止を受けて、長時間作用型プロプラノロールカプセルを発売しました。この新しい徐放性製剤は、60mg、80mg、120mg、160mgの用量があり、カナダの患者に一貫した症状緩和を提供し、アドヒアランスと治療成績を改善するとともに、ヘルスケアへのアクセスを向上させる。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界プロプラノロール医薬品 PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のプロプラノロール医薬品市場：成長率分析
• 世界のプロプラノロール医薬品市場の実績：規模と成長, 2019-2024
• 世界のプロプラノロール医薬品市場の予測：規模と成長, 2024-2029, 2034F
• 世界プロプラノロール医薬品総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のプロプラノロール医薬品市場投与量別、実績と予測, 2019-2024, 2024-2029F, 2034F
• タブレット
• 注射液
• 徐放性カプセル
• 経口溶液
• 世界のプロプラノロール医薬品市場適応症別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 高血圧
• 狭心症
• 片頭痛予防
• 心的外傷後ストレス障害（PTSD）
• 本態性振戦
• 不安障害の治療選択肢
• 世界のプロプラノロール医薬品市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• クリニック
• 在宅ヘルスケア環境
• 介護施設
• 製薬会社
• 世界のプロプラノロール医薬品市場錠剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 標準タブレット
• チュアブル錠
• フィルムコーティング錠
• 世界のプロプラノロール医薬品市場、注射液の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 静脈内溶液
• 筋肉内注射液
• プレフィルドシリンジ
• 世界のプロプラノロール医薬品市場徐放性カプセルの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 60ミリグラム（mg）
• 80ミリグラム（mg）
• 120ミリグラム（mg）
• 160ミリグラム（mg）
• 世界のプロプラノロール医薬品市場経口液のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 液体懸濁液
• 濃縮経口液
• すぐに使える経口溶液

第7章 地域別・国別分析

• 世界のプロプラノロール医薬品市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のプロプラノロール医薬品市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• プロプラノロール医薬品市場：競合情勢
• プロプラノロール医薬品市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Boehringer Ingelheim International GmbH Overview, Products and Services, Strategy and Financial Analysis
  • Sandoz Group AG Overview, Products and Services, Strategy and Financial Analysis
  • Fresenius Kabi AG Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Cipla Limited
• Hikma Pharmaceuticals PLC
• Amneal Pharmaceuticals Inc.
• Lupin Limited
• Alkem Laboratories Ltd.
• Torrent Pharmaceuticals Ltd.
• Ipca Laboratories Limited
• Mankind Pharma Ltd.
• Lannett Company Inc.
• Jubilant Pharma Holdings Inc.
• Actiza Pharmaceutical Private Limited
• Mylan Laboratories Inc.
• Neurocon Inc.
• Neuracle Lifesciences Pvt. Ltd.
• Yabang Pharmaceutical Group Co. Ltd.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• プロプラノロール医薬品市場2029：新たな機会を提供する国
• プロプラノロール医薬品市場2029：新たな機会を提供するセグメント
• プロプラノロール医薬品市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Propranolol is a non-selective beta-blocker that reduces heart rate, blood pressure, cardiac workload, anxiety, and helps in migraine prevention. It works by blocking the effects of adrenaline on the heart and blood vessels, thereby lowering heart rate and blood pressure. Propranolol is also commonly prescribed to manage symptoms of anxiety, particularly performance anxiety.

The main forms of propranolol dosage include tablets, injectable solutions, extended-release capsules, and oral solutions. Propranolol tablets are solid oral medications containing propranolol hydrochloride, designed for rapid absorption to treat conditions such as high blood pressure, arrhythmias, and anxiety. They are typically taken multiple times a day with flexible dosing. Propranolol is used for a variety of indications, including hypertension, angina pectoris, migraine prevention, post-traumatic stress disorder (PTSD), essential tremors, and therapeutic options for anxiety disorders. It is employed by a range of end-users, including hospitals, clinics, home healthcare settings, nursing homes, and pharmaceutical companies.

The propranolol drug market research report is one of a series of new reports from The Business Research Company that provides propranolol drug market statistics, including the propranolol drug industry global market size, regional shares, competitors with the propranolol drug market share, detailed propranolol drug market segments, market trends, and opportunities, and any further data you may need to thrive in the propranolol drug industry. This propranolol drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The propranolol drug market size has grown strongly in recent years. It will grow from $1.05 billion in 2024 to $1.11 billion in 2025 at a compound annual growth rate (CAGR) of 5.8%. The growth during the historic period can be attributed to factors such as the rising incidence of migraine disorders, an increasing focus on affordable healthcare solutions, growing adoption of beta-blockers in post-surgery recovery, expanding healthcare infrastructure in developing regions, and a rising demand for long-acting drug formulations.

The propranolol drug market size is expected to see strong growth in the next few years. It will grow to $1.37 billion in 2029 at a compound annual growth rate (CAGR) of 5.5%. The growth during the forecast period can be attributed to factors such as the growing demand for non-invasive treatments, increasing research and development in cardiovascular drugs, rising healthcare spending in emerging economies, and the increasing adoption of personalized medicine in cardiovascular treatments. Key trends in the forecast period include advancements in sustained-release formulations, the development of advanced drug delivery systems, innovations in personalized medicine for cardiovascular treatments, the integration of digital health tools with drug therapy, and advanced research in combination therapies for anxiety and hypertension.

The rising prevalence of cardiovascular diseases (CVDs) is expected to drive the expansion of the propranolol drug market. CVDs are a group of disorders affecting the heart and blood vessels, including conditions such as coronary artery disease, heart failure, and stroke. The increase in cardiovascular diseases is largely due to unhealthy eating habits, with excessive consumption of processed foods and fats leading to elevated cholesterol levels, which in turn raise the risk of heart-related issues. Propranolol is effective in managing these diseases by regulating heart rate and lowering blood pressure, making it particularly beneficial for patients with hypertension and arrhythmias. The drug also enhances heart function, reducing the risk of heart attacks and strokes, thus improving overall cardiovascular health. For example, in May 2024, the Centers for Disease Control and Prevention (CDC) reported that heart disease caused 702,880 deaths in 2022, accounting for one in every five deaths in the U.S. Additionally, around 805,000 people in the United States suffer a heart attack each year. Consequently, the growing prevalence of cardiovascular diseases is driving the demand for propranolol.

Key players in the propranolol drug market are focusing on developing advanced formulations, such as extended-release propranolol drugs, to improve patient adherence and overall therapeutic outcomes. Extended-release formulations are designed to gradually release the drug over time, ensuring sustained therapeutic effects and reducing the need for frequent dosing. This not only improves patient compliance but also enhances treatment effectiveness. For example, in August 2023, Lupin Pharma Canada Ltd., a pharmaceutical company based in Canada, launched long-acting propranolol capsules in response to the discontinuation of Inderal long-acting (LA). The new extended-release formulation, available in doses of 60 mg, 80 mg, 120 mg, and 160 mg, offers consistent symptom relief for Canadian patients, improving adherence and treatment outcomes, while increasing healthcare access.

In December 2024, Exicure Inc., a biotechnology company based in the U.S., entered into a partnership with GPCR Therapeutics Inc. This collaboration aims to bolster Exicure's position as a clinical-stage biotech company by acquiring technical expertise and gaining access to GPCR Therapeutics' proprietary CXCR4 inhibitor technology. This partnership enhances Exicure's drug development pipeline, particularly in the areas of immuno-oncology, fibrosis, and obesity treatments. GPCR Therapeutics Inc., based in South Korea, is also involved in the manufacturing of propranolol drugs.

Major players in the propranolol drug market are Pfizer Inc., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, Sandoz Group AG, Fresenius Kabi AG, Cipla Limited, Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals Inc., Lupin Limited, Alkem Laboratories Ltd., Torrent Pharmaceuticals Ltd., Ipca Laboratories Limited, Mankind Pharma Ltd., Lannett Company Inc., Jubilant Pharma Holdings Inc., Actiza Pharmaceutical Private Limited, Mylan Laboratories Inc., Neurocon Inc., Neuracle Lifesciences Pvt. Ltd., Yabang Pharmaceutical Group Co. Ltd.

North America was the largest region in the propranolol drug market in 2024. The regions covered in propranolol drug report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the propranolol drug market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The propranolol drug market consists of sales of intravenous (IV) infusion. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Propranolol Drug Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on propranolol drug market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for propranolol drug ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The propranolol drug market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Dosage: Tablets; Injectable Solutions; Extended-Release Capsules; Oral Solution
• 2) By Indication-Based: Hypertension; Angina Pectoris; Migraine Prevention; Post-Traumatic Stress Disorder (PTSD); Essential Tremors; Therapeutic Options In Anxiety Disorders
• 3) By End-User: Hospitals; Clinics; Home Healthcare Settings; Nursing Homes; Pharmaceutical Companies
• Subsegments:
• 1) By Tablets: Standard Tablets; Chewable Tablets; Film-Coated Tablets
• 2) By Injectable Solutions: Intravenous Solutions; Intramuscular Solutions; Pre-Filled Syringes
• 3) By Extended-Release Capsules: 60 Milligrams (mg); 80 Milligrams (mg); 120 Milligrams (mg); 160 Milligrams (mg)
• 4) By Oral Solution: Liquid Suspension; Concentrated Oral Solution; Ready-To-Use Oral Solution
• Companies Mentioned: Pfizer Inc.; Teva Pharmaceutical Industries Ltd.; Boehringer Ingelheim International GmbH; Sandoz Group AG; Fresenius Kabi AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Propranolol Drug Market Characteristics

3. Propranolol Drug Market Trends And Strategies

4. Propranolol Drug Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Propranolol Drug Growth Analysis And Strategic Analysis Framework

• 5.1. Global Propranolol Drug PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Propranolol Drug Market Growth Rate Analysis
• 5.4. Global Propranolol Drug Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Propranolol Drug Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Propranolol Drug Total Addressable Market (TAM)

6. Propranolol Drug Market Segmentation

• 6.1. Global Propranolol Drug Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Tablets
• Injectable Solutions
• Extended-Release Capsules
• Oral Solution
• 6.2. Global Propranolol Drug Market, Segmentation By Indication-Based, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hypertension
• Angina Pectoris
• Migraine Prevention
• Post-Traumatic Stress Disorder (PTSD)
• Essential Tremors
• Therapeutic Options In Anxiety Disorders
• 6.3. Global Propranolol Drug Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Clinics
• Home Healthcare Settings
• Nursing Homes
• Pharmaceutical Companies
• 6.4. Global Propranolol Drug Market, Sub-Segmentation Of Tablets, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Standard Tablets
• Chewable Tablets
• Film-Coated Tablets
• 6.5. Global Propranolol Drug Market, Sub-Segmentation Of Injectable Solutions, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Intravenous Solutions
• Intramuscular Solutions
• Pre-Filled Syringes
• 6.6. Global Propranolol Drug Market, Sub-Segmentation Of Extended-Release Capsules, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 60 Milligrams (mg)
• 80 Milligrams (mg)
• 120 Milligrams (mg)
• 160 Milligrams (mg)
• 6.7. Global Propranolol Drug Market, Sub-Segmentation Of Oral Solution, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Liquid Suspension
• Concentrated Oral Solution
• Ready-To-Use Oral Solution

7. Propranolol Drug Market Regional And Country Analysis

• 7.1. Global Propranolol Drug Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Propranolol Drug Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Propranolol Drug Market

• 8.1. Asia-Pacific Propranolol Drug Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Propranolol Drug Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Propranolol Drug Market, Segmentation By Indication-Based, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Propranolol Drug Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Propranolol Drug Market

• 9.1. China Propranolol Drug Market Overview
• 9.2. China Propranolol Drug Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Propranolol Drug Market, Segmentation By Indication-Based, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Propranolol Drug Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Propranolol Drug Market

• 10.1. India Propranolol Drug Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Propranolol Drug Market, Segmentation By Indication-Based, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Propranolol Drug Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Propranolol Drug Market

• 11.1. Japan Propranolol Drug Market Overview
• 11.2. Japan Propranolol Drug Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Propranolol Drug Market, Segmentation By Indication-Based, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Propranolol Drug Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Propranolol Drug Market

• 12.1. Australia Propranolol Drug Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Propranolol Drug Market, Segmentation By Indication-Based, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Propranolol Drug Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Propranolol Drug Market

• 13.1. Indonesia Propranolol Drug Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Propranolol Drug Market, Segmentation By Indication-Based, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Propranolol Drug Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Propranolol Drug Market

• 14.1. South Korea Propranolol Drug Market Overview
• 14.2. South Korea Propranolol Drug Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Propranolol Drug Market, Segmentation By Indication-Based, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Propranolol Drug Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Propranolol Drug Market

• 15.1. Western Europe Propranolol Drug Market Overview
• 15.2. Western Europe Propranolol Drug Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Propranolol Drug Market, Segmentation By Indication-Based, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Propranolol Drug Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Propranolol Drug Market

• 16.1. UK Propranolol Drug Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Propranolol Drug Market, Segmentation By Indication-Based, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Propranolol Drug Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Propranolol Drug Market

• 17.1. Germany Propranolol Drug Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Propranolol Drug Market, Segmentation By Indication-Based, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Propranolol Drug Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Propranolol Drug Market

• 18.1. France Propranolol Drug Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Propranolol Drug Market, Segmentation By Indication-Based, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Propranolol Drug Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Propranolol Drug Market

• 19.1. Italy Propranolol Drug Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Propranolol Drug Market, Segmentation By Indication-Based, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Propranolol Drug Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Propranolol Drug Market

• 20.1. Spain Propranolol Drug Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Propranolol Drug Market, Segmentation By Indication-Based, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Propranolol Drug Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Propranolol Drug Market

• 21.1. Eastern Europe Propranolol Drug Market Overview
• 21.2. Eastern Europe Propranolol Drug Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Propranolol Drug Market, Segmentation By Indication-Based, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Propranolol Drug Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Propranolol Drug Market

• 22.1. Russia Propranolol Drug Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Propranolol Drug Market, Segmentation By Indication-Based, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Propranolol Drug Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Propranolol Drug Market

• 23.1. North America Propranolol Drug Market Overview
• 23.2. North America Propranolol Drug Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Propranolol Drug Market, Segmentation By Indication-Based, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Propranolol Drug Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Propranolol Drug Market

• 24.1. USA Propranolol Drug Market Overview
• 24.2. USA Propranolol Drug Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Propranolol Drug Market, Segmentation By Indication-Based, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Propranolol Drug Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Propranolol Drug Market

• 25.1. Canada Propranolol Drug Market Overview
• 25.2. Canada Propranolol Drug Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Propranolol Drug Market, Segmentation By Indication-Based, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Propranolol Drug Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Propranolol Drug Market

• 26.1. South America Propranolol Drug Market Overview
• 26.2. South America Propranolol Drug Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Propranolol Drug Market, Segmentation By Indication-Based, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Propranolol Drug Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Propranolol Drug Market

• 27.1. Brazil Propranolol Drug Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Propranolol Drug Market, Segmentation By Indication-Based, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Propranolol Drug Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Propranolol Drug Market

• 28.1. Middle East Propranolol Drug Market Overview
• 28.2. Middle East Propranolol Drug Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Propranolol Drug Market, Segmentation By Indication-Based, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Propranolol Drug Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Propranolol Drug Market

• 29.1. Africa Propranolol Drug Market Overview
• 29.2. Africa Propranolol Drug Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Propranolol Drug Market, Segmentation By Indication-Based, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Propranolol Drug Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Propranolol Drug Market Competitive Landscape And Company Profiles

• 30.1. Propranolol Drug Market Competitive Landscape
• 30.2. Propranolol Drug Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Boehringer Ingelheim International GmbH Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Sandoz Group AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Fresenius Kabi AG Overview, Products and Services, Strategy and Financial Analysis

31. Propranolol Drug Market Other Major And Innovative Companies

• 31.1. Cipla Limited
• 31.2. Hikma Pharmaceuticals PLC
• 31.3. Amneal Pharmaceuticals Inc.
• 31.4. Lupin Limited
• 31.5. Alkem Laboratories Ltd.
• 31.6. Torrent Pharmaceuticals Ltd.
• 31.7. Ipca Laboratories Limited
• 31.8. Mankind Pharma Ltd.
• 31.9. Lannett Company Inc.
• 31.10. Jubilant Pharma Holdings Inc.
• 31.11. Actiza Pharmaceutical Private Limited
• 31.12. Mylan Laboratories Inc.
• 31.13. Neurocon Inc.
• 31.14. Neuracle Lifesciences Pvt. Ltd.
• 31.15. Yabang Pharmaceutical Group Co. Ltd.

32. Global Propranolol Drug Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Propranolol Drug Market

34. Recent Developments In The Propranolol Drug Market

35. Propranolol Drug Market High Potential Countries, Segments and Strategies

• 35.1 Propranolol Drug Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Propranolol Drug Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Propranolol Drug Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer